Provided by Tiger Trade Technology Pte. Ltd.

Protagenic Therapeutics Inc

1.67
-0.0100-0.60%
Post-market: 1.65-0.0192-1.15%18:19 EST
Volume:83.54K
Turnover:140.73K
Market Cap:3.23M
PE:-0.13
High:1.80
Open:1.71
Low:1.60
Close:1.68
52wk High:14.28
52wk Low:1.60
Shares:1.93M
Float Shares:1.91M
Volume Ratio:0.76
T/O Rate:4.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.0507
EPS(LYR):-15.7868
ROE:-512.79%
ROA:-189.60%
PB:-36.58
PE(LYR):-0.11

Loading ...

Protagenic Therapeutics Inc. Announces Date for Upcoming Annual Stockholders Meeting

Reuters
·
Yesterday

Sector Update: Health Care Stocks Mixed Premarket Friday

MT Newswires Live
·
Nov 28

Protagenic Therapeutics Faces Nasdaq Delisting Due to Compliance Issues

MT Newswires Live
·
Nov 28

Protagenic Therapeutics Delays Quarterly Financial Report

Reuters
·
Nov 27

Protagenic Therapeutics Delays Quarterly Report Filing

Reuters
·
Nov 15

Protagenic Therapeutics Completes Dosing in Phase 1 Study of Lead Compound PT00114

Reuters
·
Nov 13

Jennifer Chao Resigns from Protagenic Therapeutics Board

Reuters
·
Nov 06

Protagenic Therapeutics Inc: Files Complaint to Rescind Share Exchange Agreement by Which Co Acquired Phytanix Bio - SEC Filing

THOMSON REUTERS
·
Nov 01

Protagenic Therapeutics: May Offer and Sell Shares of Common Stock of up to $1.75 Mln - SEC Filing

THOMSON REUTERS
·
Oct 25

Protagenic Therapeutics Files Initial Beneficial Ownership Statement; Ex-CEO and Director Barrett Evans Named as 10% Owner

Reuters
·
Oct 25

Top Midday Gainers

MT Newswires Live
·
Aug 22

Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Phase 2 for Stress & Mood Disorders Set for 1Q 2026

Reuters
·
Aug 21

Protagenic Therapeutics Inc. Delays Q2 Financial Report Due to Transition to Virtual Operating Model

Reuters
·
Aug 15

BRIEF-Protagenic Therapeutics Approves Restructuring Plan on August 8- SEC Filing

Reuters
·
Aug 14

Protagenic Therapeutics to Pause Trials, Remove CEO in Restructuring

Dow Jones
·
Aug 14

Protagenic Therapeutics Inc: Has Temporarily Suspended Expenditures Related to Preclinical Programs

THOMSON REUTERS
·
Aug 14

Protagenic Therapeutics : Terminated Employment of Barrett Evans as CEO and President and Colin Stott as Chief Operating Officer

THOMSON REUTERS
·
Aug 14

Protagenic Therapeutics:All Preclinical Programs Originated With Former Phytanix Bio (Phyx-001,Phyx-002,Phyx-003,Phyx-004, Phyx-005) Have Been Paused

THOMSON REUTERS
·
Aug 14

Protagenic Therapeutics Inc: Initiated Process to Evaluate Strategic Alternatives for Those Programs, Including Partnerships and/or Out-Licensing

THOMSON REUTERS
·
Aug 14

Protagenic Therapeutics Inc: Approved a Change in Co's Fiscal Year-End From December 31 to March 31, Effective Immediately

THOMSON REUTERS
·
Aug 14